通过抗白细胞介素-6受体抗体（托珠单抗）成功治疗伴有卡斯特曼病的系膜增生性肾小球肾炎合并间质性肾炎。
Successful treatment of a mesangial proliferative glomerulonephritis with interstitial nephritis associated with Castleman's disease by an anti-interleukin-6 receptor antibody (tocilizumab).
作者信息
Otani Naoko, Morishita Yoshiyuki, Oh Iekuni, Saito Osamu, Takemoto Fumi, Muto Shigeaki, Kusano Eiji
机构信息
Division of Nephrology, Department of Internal Medicine, Jichi Medical University, Japan.
出版信息
Intern Med. 2012;51(11):1375-8. doi: 10.2169/internalmedicine.51.6555. Epub 2012 Jun 1.
We report a case of mesangial proliferative glomerulonephritis with interstitial nephritis associated with multicentric Castleman's disease (MCD) successfully treated with an anti-interleukin-6 receptor antibody (tocilizumab). This mesangial proliferative glomerulonephritis with interstitial nephritis was resistant to methylprednisolone treatment; however, it was markedly improved with tocilizumab, which was administered intravenously at a dose of 8 mg/kg every 2 weeks. These results suggest that tocilizumab is effective for the treatment of mesangial proliferative glomerulonephritis with interstitial nephritis associated with MCD.
我们报告了1例伴有间质性肾炎的系膜增生性肾小球肾炎合并多中心Castleman病（MCD）患者，该患者接受抗白细胞介素-6受体抗体（托珠单抗）治疗成功。这种伴有间质性肾炎的系膜增生性肾小球肾炎对甲泼尼龙治疗耐药；然而，使用托珠单抗后病情明显改善，托珠单抗以每2周8 mg/kg的剂量静脉给药。这些结果表明，托珠单抗对治疗伴有MCD的伴有间质性肾炎的系膜增生性肾小球肾炎有效。
Zotero 插件